Current Opinion in Hematology volume 19, issue 4, P280-286 2012 DOI: 10.1097/moh.0b013e3283545615 View full text
|
|
Share
Tsz K. Fung, Arnaud Gandillet, Chi W.E. So

Abstract: On the basis of the results from preclinical model studies, a combination treatment targeting both GSK3 and the canonical Wnt signaling pathway emerges as a promising avenue to eradicate MLL LSCs. Future effort in identifying the key tractable components along these signaling pathways will be critical for the development of effective inhibitors to target this aggressive disease.